Challenge of pediatric oncology in Africa

Larry G P Hadley1, Bankole S Rouma, Yasser Saad-Eldin

  • 1Department of Paediatric Surgery, University of KwaZulu-Natal, Durban, South Africa. HADLEY@ukzn.ac.za

Insights

Childhood cancer care in sub-Saharan Africa faces severe resource limitations, leading to late diagnoses and poor survival rates. Improving pediatric surgical oncology requires infrastructure development alongside specialized expertise.

Area of Science:

  • Pediatric Surgical Oncology
  • Global Health
  • Cancer Epidemiology in Africa

Background:

  • Sub-Saharan Africa faces significant challenges in pediatric cancer care due to resource deficiencies.
  • Inadequate healthcare budgets, personnel shortages, and limited facilities compromise treatment.
  • Patients experience difficulties in accessing care, affording treatments, and attending follow-ups, often presenting with advanced disease.

Purpose of the Study:

  • To discuss the patterns of childhood solid malignant tumors in Africa.
  • To highlight the management difficulties encountered in resource-limited settings.
  • To review the experiences of pediatric surgeons and available literature on the topic.

Main Methods:

  • Review of available literature on pediatric solid malignant tumors in Africa.
  • Reflection on experiences from three pediatric surgeons across different African regions.
  • Analysis of reported incidence and survival rates from various countries.

Main Results:

  • Estimating incidence is difficult due to lack of vital statistics and cancer registries.
  • Reported incidences of pediatric solid tumors range from 5% to 15.5% of all malignant tumors.
  • Patterns vary, with increased Burkitt lymphoma (BL) and Kaposi sarcoma prevalence linked to HIV; leukemia is common in North Africa, while BL dominates sub-Saharan regions.
  • Survival rates are critically low, with 5-year survival varying widely (5% to 70%) and often unmentioned in many reports.
  • Late presentation is common, with high percentages of advanced stages for tumors like nephroblastoma and BL.
  • Over 80% of children in Africa die without adequate treatment, contrasting with high survival rates in developed countries.

Conclusions:

  • Pediatric surgical oncology is not prioritized by governments, despite its potential cost-effectiveness.
  • Addressing infrastructural deficiencies is crucial and must accompany the development of specialized expertise.
  • Improving pediatric cancer care requires a comprehensive approach involving resource development and policy changes.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...